The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running.
The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it?
The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia).
To view the multimedia release go to:
http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/
One day in the early 21st century the four horseman of the Apocalypse decided not to end the world and attempt to live on Earth as humans. Scarlet is the horseman of War and guards a great sword as her seal. Bianca is the horseman of Conquest and guards a crown as her seal. Katherine is the horseman of Famine and guards a set of scales as her seal. Finally, Cloris is the horseman of Death and guards the God of the Underworld Hades as her seal. The horseman might want to forget about the apocalypse but there are others who aren’t in agreement. The Goddess Hel wants Hades back and is willing to sacrifice the Earth and the horseman to make it happen. find out more at www.monicacorwinauthor.net Romance/fantasy
Persil® ProClean®, Henkel North America’s new premium laundry detergent brand, made its first-ever Super Bowl® advertising debut with a commercial that aired in the second quarter of Super Bowl 50. As a new brand in the U.S. Persil ProClean has only been available to U.S. consumers since early 2015, but the Persil brand has been globally renowned for over a century. Its exceptional stain-fighting, whitening, and freshness have translated into impressive repeat-purchase rates, showing that once consumers try it, they love it.
Persil ProClean chose this coveted platform to launch their 2016 advertising campaign featuring the brand’s debonair tuxedo-wearing, stain-fighting superhero, “The Professional,” played by Peter Hermann. “The Professional” brings humor to a historically predictable category, while showing off some serious stain-fighting to relay a simple yet impactful message to viewers. Packed with powerful stain-fighting technology, Persil ProClean 2in1, received the highest laundry detergent rating in recent rankings by a leading consumer testing publication. Persil ProClean 2in1 didn’t only beat market-leader Tide, it beat every single detergent tested.
To view the multimedia release go to:
http://www.multivu.com/players/English/7750351-persil-proclean-super-bowl/
This candid, autobiographical book tells of Jay’s journey to find his identity and his own version of “happy” in early adulthood through self-destructive means like alcohol, a myriad of drugs, and other risky behavior, and how he pulled himself back from the edge of the abyss, finding the courage to live a life of clarity and purpose after discovering what true, lasting happiness in life is all about. Find out more at -http://www.amazon.com/Jerome-Jay-Isip/e/B00PB2P6SS/ref=ntt_dp_epwbk_1 Biography, Memoir, Self-Help
The winter of 2015-2016 is in its early stages, and yet many parts of the country are already experiencing extreme weather conditions and power outages. In fact, a power outage can happen at any time, and it can affect the safety of your food. The U.S. Food and Drug Administration reminds you that the best way to ensure that food stays safe is to have a plan in place, and to know what food safety precautions to take if a power outage does occur.
To view the multimedia release go to:
http://www.multivu.com/players/English/7674751-fda-power-outage-food-safety/
Jewelry Television (JTV), the only shopping network focused exclusively on the sale of fine jewelry and gemstones, is celebrating the holiday season with eight days of exclusive savings and offers. From Nov. 23 through Nov. 30, JTV's customers will be able to purchase select gifts and jewelry up to 70 percent off. Early holiday shoppers can take advantage of special offers and savings on jewelry, gemstones and more each day, online and during programming on JTV.
“Every year, holiday shoppers try to get an earlier head start on their shopping,” said Jill Johnson, vice president of marketing at JTV. “With our weeklong Black Friday and Cyber Monday deals, customers can enjoy the holidays with their families while shopping from home.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7372631-jewelry-television/
Dickey’s Barbecue Restaurants, Inc. is vigorously preparing for Thanksgiving, so you don’t have to. Last year, according to the National Restaurant Association, over 33 million Americans relied on restaurants for at least a part of their Thanksgiving meal. Dickey’s sold 400,000 pounds of holiday turkeys and hams nationwide in 2014 and that number is projected to increase by more than 20% this year.
With the recent bird flu outbreak, many Americans have supply concerns when it comes to their holiday turkey. Some chains have even pulled turkey from their menus nationwide due to the shortage leading to increased costs. The national barbecue chain worked to secure its holiday supply early, prior to the shortage, which is just another way Dickey’s prepares for the holiday season so you don’t have to. Guests can rely on Dickey’s Barbecue Pit to provide holiday meats and complete feasts for an affordable and delicious holiday celebration.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7434753-dickey-s-barbecue-pit-thanksgiving/
Portland, Oregon has the best preterm birth rate of the top 100 cities with the most births nationwide, while Shreveport, Louisiana has the worst, according to the 2015 March of Dimes Premature Birth Report Card, which for the first time graded cities and counties around the nation and revealed persistent racial, ethnic and geographic disparities within states.
The U.S. preterm birth rate ranks among the worst of high-resource countries, the March of Dimes says. Worldwide, 15 million babies are born preterm, and nearly one million die due to early birth or its complications. Babies who survive an early birth often face serious and lifelong health problems, including breathing problems, jaundice, vision loss, cerebral palsy and intellectual delays.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7653351-march-of-dimes-premature-birth-report/
Autism Speaks – the world’s leading autism science and advocacy organization – today joined the Ad Council and BBDO New York, the long-time volunteer agency for Autism Speaks, to announce the launch of a new series of public service advertisements (PSAs) designed to help parents recognize the early signs of autism and take immediate action. For the first time in the campaign’s history, the new PSAs feature an imaginative world, created using 3D and stop-motion animation, inspired by stories of real children with autism and told from the perspective of a child with autism. The PSAs are an extension of the award-winning “Learn the Signs” campaign, created by BBDO, which has helped significantly increase the percentage of parents who recognize the early warning signs of autism.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7674151-ad-council-autism-speaks-psa-s-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
